KM10544 / Kainos Medicine, Emmaus - LARVOL DELTA

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights (PRNewswire) - "'In October, we expanded our pipeline by obtaining an exclusive license to the intellectual property surrounding Kainos' IRAK4 inhibitor a novel potential treatment option for some of the hard-to-treat lymphomas such as Waldenström's Macroglobulinemia with MYD88 mutation, and others.'"

Pipeline update • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine (PRNewswire) - "Emmaus Life Sciences, Inc...announced the signing of an agreement with Kainos Medicine, Inc. (Kainos), granting Emmaus an exclusive license to patent rights, know-how and other intellectual property relating to Kainos' novel IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers including leukemia, lymphoma and solid tumors. The license agreement expands upon the existing research and development collaboration agreement between the parties. Financial details of the agreement were not disclosed."

Licensing / partnership • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug (PRNewswire) - "Emmaus Life Sciences, Inc...announced today that it has entered into an agreement with Kainos Medicine, Inc...to lead the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos. With this agreement in place, Kainos plans to complete the study of the therapeutic mechanism of action..of KM10544 in solid cancers, blood cancers and lymphoma. Emmaus will be responsible for the investigation and proof of target disease selection, efficacy and safety."

Licensing / partnership